Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Plasma Cell-free RNA PD-L1 Expression and Overall Survival of Immune Checkpoint Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer

Paul R. Walker
* ORCID logo ,
Mahvish Muzzafar
ORCID logo ,
Sriraksha Jayananda
,
Praveen Namireddy
,
Nitika Sharma
,
Teresa Parent
,
Cynthia Cherry
,
Richard B. Lanman
Version 1 : Received: 14 July 2022 / Approved: 11 August 2022 / Online: 11 August 2022 (06:10:34 CEST)

How to cite: Walker, P.R.; Muzzafar, M.; Jayananda, S.; Namireddy, P.; Sharma, N.; Parent, T.; Cherry, C.; Lanman, R.B. Plasma Cell-free RNA PD-L1 Expression and Overall Survival of Immune Checkpoint Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer. Preprints 2022, 2022080208. https://doi.org/10.20944/preprints202208.0208.v1 Walker, P.R.; Muzzafar, M.; Jayananda, S.; Namireddy, P.; Sharma, N.; Parent, T.; Cherry, C.; Lanman, R.B. Plasma Cell-free RNA PD-L1 Expression and Overall Survival of Immune Checkpoint Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer. Preprints 2022, 2022080208. https://doi.org/10.20944/preprints202208.0208.v1

Abstract

Tissue programmed death ligand-1 (PD-L1) protein expression is predictive of immune checkpoint inhibitor (ICI) benefit. However, tissue PD-L1 can be fraught with tissue acquisition and heterogeneity limitations. Plasma testing can overcome these limitations. However, the overall survival (OS) predictive benefit of plasma PD-L1 assays have not been well characterized. Patients with stage IV non-small cell lung cancer (NSCLC) and plasma cfRNA PD-L1 by PCR expression were identified and assessed for OS. 16 patients treated with front-line ICI-based regimens were assessed and represented a real-world patient population with over half with a performance status of 2 or greater. 10 contemporaneous patients at the same institution treated with chemotherapy alone were also identified and assessed. With a median follow-up of 33 months, median OS was 13 months with a 30% 3-year OS for the ICI treated patients compared to a median OS of 3 months and a 10% 3-year OS for those treated with chemotherapy alone. Comparative log-rank test p-value = 0.014 and a hazard ratio 0.376 (95%-CI 0.134-1.057). Plasma cfRNA PD-L1 was associated with a statistically significant survival benefit from ICI-based treatment compared to chemotherapy in the first line treatment of a real-world patient population of advanced NSCLC.

Keywords

Plasma PD-L1; liquid biopsy; cfRNA; immune checkpoint inhibitor; predictive immune biomarker; NSCLC

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.